Feature

Trial to assess hydroxychloroquine for COVID-19 prevention during cancer treatment

May 22, 2020
A randomized phase 2 clinical trial will assess hydroxychloroquine for prevention of COVID-19 infection among patients undergoing radiation therapy…
In the Journals

FDA using surrogate endpoints more frequently to approve cancer drugs

May 19, 2020
The FDA increasingly is using surrogate endpoints to support approval of cancer drugs, according to results of a retrospective review in a research…
In the JournalsPerspective

Higher dose of CAR T cells may be more effective in advanced chronic lymphocytic leukemia

May 18, 2020
A higher dose of anti-CD19 chimeric antigen receptor T cells may lead to more complete responses among patients with relapsed or refractory chronic…
In the Journals

Atezolizumab plus bevacizumab improves survival outcomes vs. sorafenib in unresectable HCC

May 13, 2020
Atezolizumab in combination with bevacizumab improved OS and PFS compared with sorafenib among patients with unresectable hepatocellular carcinoma…
In the Journals

New insights into cancer-related cognitive impairment help dispel notion of ‘chemo brain’

May 12, 2020
Adjuvant chemotherapy plus endocrine therapy appeared to produce early — but not sustained — cognitive impairment compared with endocrine…
Meeting NewsPerspective

Novel CD19/CD22 bispecific CAR-T effective, safe for advanced pediatric ALL

May 1, 2020
A novel bispecific chimeric antigen receptor T-cell therapy appeared safe and effective for younger patients with relapsed or refractory acute…
Feature

Proton pump inhibitors may lead to cognitive decline among breast cancer survivors

April 24, 2020
Breast cancer survivors often take proton pump inhibitors to manage gastrointestinal symptoms related to their treatment. Physicians also may…
In the Journals

Ruxolitinib effective, safe for glucocorticoid-refractory acute GVHD

April 22, 2020
Ruxolitinib appeared to be more effective than common treatments for patients with glucocorticoid-refractory acute graft-versus-host-disease…
In the Journals

Pembrolizumab regimen confers substantial survival benefit in untreated metastatic nonsquamous NSCLC

April 20, 2020
First-line pembrolizumab in combination with pemetrexed and platinum-based chemotherapy substantially extended PFS and OS among patients with…
In the Journals

Subcutaneous daratumumab noninferior to IV formulation, more tolerable for advanced multiple myeloma

April 14, 2020
A subcutaneous formulation of daratumumab appeared noninferior to the standard IV formulation among patients with relapsed or refractory multiple…
Healio Jobs